Earnings summaries and quarterly performance for Alkermes.
Executive leadership at Alkermes.
Richard F. Pops
Detailed
Chief Executive Officer
CEO
BC
Blair C. Jackson
Detailed
Executive Vice President, Chief Operating Officer and Chief Risk Officer
CT
C. Todd Nichols
Detailed
Senior Vice President, Chief Commercial Officer
CC
Craig C. Hopkinson
Detailed
Executive Vice President, Research and Development and Chief Medical Officer
DJ
David J. Gaffin
Detailed
Executive Vice President, Chief Legal Officer and Chief Compliance Officer
JR
Joshua Reed
Detailed
Senior Vice President, Chief Financial Officer
Board of directors at Alkermes.
Research analysts who have asked questions during Alkermes earnings calls.
David Amsellem
Piper Sandler Companies
4 questions for ALKS
Also covers: ABBV, AMGN, AMPH +27 more
DT
Douglas Tsao
H.C. Wainwright & Co.
4 questions for ALKS
Also covers: APLS, ARGX, ARQT +19 more
Joseph Thome
TD Cowen
4 questions for ALKS
Also covers: AMLX, ARDX, ARWR +12 more
MG
Marc Goodman
Leerink Partners
4 questions for ALKS
Also covers: ACAD, ALDX, AMLX +14 more
Paul Matteis
Stifel
4 questions for ALKS
Also covers: ABOS, ACAD, ALNY +11 more
UR
Umer Raffat
Evercore ISI
4 questions for ALKS
Also covers: AMGN, BHC, BIIB +15 more
UE
Uy Ear
Mizuho Securities
4 questions for ALKS
Also covers: ARQT, EOLS, NBIX +6 more
CD
Charles Duncan
Cantor Fitzgerald & Co.
3 questions for ALKS
Also covers: ACAD, ATAI, AXSM +12 more
Jason Gerberry
Bank of America Merrill Lynch
3 questions for ALKS
Also covers: AMPH, ARWR, AXSM +23 more
JF
Jessica Fye
JPMorgan Chase & Co.
3 questions for ALKS
Also covers: ALNY, AMRN, ASND +23 more
JB
Joel Beatty
Baird
3 questions for ALKS
Also covers: ACAD, AMLX, ARGX +11 more
Leonid Timashev
RBC Capital Markets
3 questions for ALKS
Also covers: ADCT, AXSM, CMPS +8 more
Akash Tewari
Jefferies
2 questions for ALKS
Also covers: APLS, ARGX, ARVN +15 more
Ami Fadia
Needham & Company, LLC
2 questions for ALKS
Also covers: ACAD, AVDL, AXSM +10 more
AV
Ashwani Verma
UBS Group AG
2 questions for ALKS
Also covers: ACAD, ALVO, AXSM +12 more
DH
David Hoang
Citigroup
2 questions for ALKS
Also covers: ACAD, AVDL, AXSM +8 more
Adam Ferrari
J.P. Morgan
1 question for ALKS
Also covers: BMRN, HALO, IMCR
Anastasia Parafestas
Jefferies
1 question for ALKS
Also covers: EXEL
AN
Andrea Newkirk
Goldman Sachs
1 question for ALKS
Also covers: ABCL, ARWR, DAWN +9 more
Ben Burnett
Stifel
1 question for ALKS
Also covers: ALLO, FATE, IDYA +1 more
Chi Eze
Bank of America
1 question for ALKS
CS
Chris Shibutani
Goldman Sachs Group, Inc.
1 question for ALKS
Also covers: ABBV, BMY, BNTX +11 more
DA
David Amsalem
Piper Sandler
1 question for ALKS
DH
David Huang
Deutsche Bank
1 question for ALKS
Also covers: APD, LIN, NBIX
H
Hoyanon
UBS
1 question for ALKS
Karishma Raghuram
Goldman Sachs
1 question for ALKS
Also covers: EXEL, RVNC
Katherine Wang
Jefferies
1 question for ALKS
Also covers: APLS, IRWD
LK
Lou Kerman
Baird
1 question for ALKS
MR
Manoj Radder
Jefferies
1 question for ALKS
MG
Mark Goodwin
Leerink Partners
1 question for ALKS
OR
Omar Rafat
Evercore ISI
1 question for ALKS
PM
Paul Matisse
Stifel Financial Corp.
1 question for ALKS
Also covers: ABOS
TL
Troy Langford
TD Cowen
1 question for ALKS
Also covers: AXSM, JAZZ, NTLA
Yuri
Mizuho
1 question for ALKS
Recent press releases and 8-K filings for ALKS.
Alkermes Highlights 2025 Performance and Strategic Growth Initiatives
ALKS
Revenue Acceleration/Inflection
New Projects/Investments
M&A
- Alkermes' commercial business generated more than $1.4 billion in total revenues in 2025.
- The company plans to close the acquisition of Avidel and its commercial narcolepsy drug Lumryz in Q1 2026, which is expected to be accretive and accelerate its entry into the sleep medicine market. Lumryz generated approximately $250 million in sales over the last trailing 12-month period.
- ALKS 2680, an orexin compound, received FDA Breakthrough Therapy designation in narcolepsy type 1 (NT1) at the end of 2025 and is scheduled to initiate its registrational Phase 3 program for narcolepsy in Q1 2026. The market opportunity for orexins in narcolepsy and idiopathic hypersomnia (IH) is estimated to be in excess of $10 billion annually.
- ALKS 2680 demonstrated statistically significant and clinically meaningful improvements in Phase 2 studies for narcolepsy type 1 and type 2, with the idiopathic hypersomnia Phase 2 study expected to complete in Q4 2026.
Jan 13, 2026, 6:30 PM
Alkermes Outlines 2026 Growth Strategy, Advances Pipeline, and Anticipates Avadel Acquisition Close
ALKS
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- Alkermes' acquisition of Avadel Pharmaceuticals plc is expected to close in Q1 2026, accelerating its entry into the commercial sleep medicine market with LUMRYZ™ and is anticipated to be accretive and enhance profitability in 2026.
- The company plans to initiate the registrational phase 3 narcolepsy program for alixorexton in Q1 2026, a candidate that has received FDA Breakthrough Therapy designation for Narcolepsy Type 1 (NT1) and demonstrated positive phase 2 data.
- Alkermes' commercial business generated total revenues exceeding $1.45 billion in 2025, with pro forma key product revenues (including LUMRYZ™) growing from $715 million in FY 2021 to $1,563 million in the rolling 12 months ending Q3 2025.
- The company is also advancing other orexin 2 receptor agonist candidates, including ALKS 4510 for fatigue (Phase 2 initiation H2 2026) and ALKS 7290 for ADHD (Phase 1b data/Phase 2 initiation H2 2026).
Jan 13, 2026, 6:30 PM
Alkermes Discusses 2025 Performance and 2026 Growth Strategy
ALKS
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- Alkermes' commercial business generated more than $1.4 billion in total revenues in 2025, demonstrating strong cash flow and profitability.
- The company's most advanced orexin compound, ALKS 2680, is entering Phase 3 in narcolepsy and was granted FDA Breakthrough Therapy designation in NT1. The market opportunity for narcolepsy and idiopathic hypersomnia (IH) alone is estimated to be in excess of $10 billion.
- Alkermes is acquiring Avidel, which includes its commercial narcolepsy drug Lumryz, an FDA-approved medicine that generated $390 million of cumulative sales since its launch two years ago and approximately $250 million in the last trailing 12-month period. This acquisition is expected to be accretive and enhance profitability in 2026.
- For 2026, Alkermes plans to initiate the ALKS 2680 registrational Phase 3 narcolepsy program in Q1 and complete its idiopathic hypersomnia Phase 2 study in Q4.
Jan 13, 2026, 6:30 PM
Alkermes Reports Strong 2025 Commercial Revenue, Advances ALKS 2680 to Phase 3, and Expects Avidel Acquisition to Close
ALKS
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- Alkermes' commercial business generated more than $1.4 billion in total revenues in 2025, demonstrating strong cash flow and profitability.
- The planned acquisition of Avidel is expected to close this quarter, augmenting revenue growth, diversifying the commercial portfolio, and enhancing profitability in 2026. Avidel's narcolepsy drug, Lumryz, has generated $390 million of cumulative sales since launch and approximately $250 million in the last trailing 12-month period.
- ALKS 2680, an advanced orexin compound, is entering Phase 3 in narcolepsy in Q1 2026 and received FDA Breakthrough Therapy designation in NT1 at the end of 2025. The market opportunity for narcolepsy and idiopathic hypersomnia is estimated to be in excess of $10 billion annually.
- The company is also progressing other pipeline candidates, with 4510 initiating a multi-dose Phase 2A study for fatigue in MS and Parkinson's disease, and 7290 moving to Phase 2 in 2026.
Jan 13, 2026, 6:30 PM
Alkermes plc. Provides 2025 Financial Highlights and 2026 Strategic Outlook
ALKS
M&A
Guidance Update
New Projects/Investments
- Alkermes' commercial business generated over $1.45 billion in total revenues in 2025, demonstrating strong cash flow and profitability.
- The company plans to close the acquisition of Avadel Pharmaceuticals plc in Q1 2026, which is expected to augment revenue growth, diversify the commercial portfolio, accelerate entry into the sleep medicine market, and be accretive and enhance profitability in 2026.
- Alixorexton, a development candidate with blockbuster potential, received FDA Breakthrough Therapy designation in Narcolepsy Type 1 (NT1) and is slated to enter Phase 3 in narcolepsy in Q1 2026.
- Topline data from the LUMRYZ™ (sodium oxybate) idiopathic hypersomnia Phase 3 study is anticipated in Q2 2026, with LUMRYZ™ holding patent protection until 2042.
Jan 12, 2026, 1:00 PM
Alkermes' alixorexton receives FDA Breakthrough Therapy designation
ALKS
New Projects/Investments
- Alkermes plc announced on January 6, 2026, that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).
- Alixorexton is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist.
- This designation was based on positive phase 1 and phase 2 clinical data, including results from the Vibrance-1 study, which demonstrated statistically significant and dose-dependent improvements in wakefulness.
- Alkermes plans to initiate the global phase 3 development program for alixorexton in the first quarter of 2026.
Jan 6, 2026, 12:06 PM
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton
ALKS
New Projects/Investments
- Alkermes plc received Breakthrough Therapy designation from the U.S. FDA for alixorexton, an investigational oral drug for the treatment of narcolepsy type 1 (NT1).
- This designation is supported by positive phase 1 and phase 2 clinical data, including the Vibrance-1 study, which demonstrated statistically significant and dose-dependent improvements in wakefulness for NT1 patients.
- Alkermes plans to initiate the global phase 3 program for alixorexton in the first quarter of 2026.
Jan 6, 2026, 12:00 PM
Alkermes Discusses Elixirxton's Clinical Development and Market Opportunity
ALKS
Product Launch
New Projects/Investments
- Alkermes' CEO Richard Pops expressed high confidence in Elixirxton's approval for Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2), based on positive Vibrance-1 and Vibrance-2 clinical data.
- The Vibrance-2 study for NT2 demonstrated statistically and clinically significant changes, with 70% of patients at the 18mg dose achieving normalcy on the ESS score.
- Alkermes plans to leverage dosing flexibility for Elixirxton, including potential split dosing, given its favorable tolerability profile with no dose-limiting toxicity observed up to 18mg.
- Phase 3 study designs for NT1 and NT2 have been finalized, with the FDA expected to recommend 40-50 patients per arm and likely 3-4 active dosing arms for NT2.
- The company anticipates similar efficacy signals for Elixirxton in Idiopathic Hypersomnia (IH) from the Vibrance-3 study, with the Epworth Sleepiness Scale (ESS) as the primary endpoint.
Dec 4, 2025, 5:00 PM
Alkermes Provides Update on Elixirxton Clinical Development and Strategy
ALKS
New Projects/Investments
Product Launch
- Alkermes' Elixirxton (ALKS 2680) is anticipated to have a high probability of approval for Narcolepsy Type 1 (NT1) and its labeling is expected to extend to Narcolepsy Type 2 (NT2), based on Vibrance-1 and Vibrance-2 study data.
- In the Vibrance-2 study for NT2, Elixirxton demonstrated statistically significant and clinically significant changes, with 70% of patients at the 18-milligram dose achieving normalcy on the Epworth Sleepiness Scale (ESS) score.
- The company has observed no dose-limiting toxicity in NT2 patients at tested doses, allowing for significant dosing flexibility in future development, including a potential anchor once-daily (QD) 18-milligram dose and split dosing options.
- Alkermes has finalized phase 3 dosing for both NT1 and NT2, with the end-of-phase-two meeting briefing book submitted this week, and the FDA is expected to recommend 40 to 50 patients per arm for these studies.
- Alkermes believes Elixirxton will show similar efficacy in Idiopathic Hypersomnia (IH) as observed in NT2, with ESS designated as the primary endpoint for the IH study.
Dec 4, 2025, 5:00 PM
Alkermes Discusses Transformational Year, Avadel Acquisition, and ALKS 2680 Progress
ALKS
M&A
New Projects/Investments
Product Launch
- Alkermes has experienced a transformational year, marked by positive NT1 and NT2 data and the announced intention to acquire Avadel.
- The company plans to acquire Avadel, a profitable company with $275 million of sales this year, to aggressively move into the hypersomnia market and leverage its commercial infrastructure for the launch of ALKS 2680.
- Positive Phase 2 data for ALKS 2680 in narcolepsy (NT1 and NT2) showed significant effects on cognition and fatigue, with Phase 3 trials for narcolepsy expected to kick off in Q1 next year (2026).
- Alkermes intends to aggressively fund its orexin program for new indications while maintaining robust profitability.
Dec 3, 2025, 7:10 PM
Quarterly earnings call transcripts for Alkermes.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more